Feedback
Settings

Settings

Goto Application

1,947 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(DXEJZRDJXRVUPN-XUTVFYLZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 195
1.WO/2025/255393HERPES SIMPLEX VIRUS ANTIGEN BINDING AGENTS FOR MITIGATION OF HERPES SIMPLEX VIRUS ASSOCIATED DISEASE
WO - 11.12.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No PCT/US2025/032531 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor COHEN, Gary H.
Provided herein are compositions for the prevention and treatment of genital herpes, comprising antigen binding agents to herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, ribonucleic acids (RNAs) encoding these antigen binding agents, and methods of use thereof.
2.WO/2025/255199ARGININOSUCCINATE SYNTHASE 1 AND ARGININOSUCCINATE LYASE POLYPEPTIDES AND POLYNUCLEOTIDES AND USES THEREOF
WO - 11.12.2025
Int.Class A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
 Appl.No PCT/US2025/032201 Applicant MODERNATX, INC. Inventor BRUNDAGE, Meghan
This disclosure relates to mRNA therapy for the treatment of citrullinemia type 1 (CTLN1) and related diseases, disorders or conditions. mRNAs for use in the invention, when administered in vivo, encode the argininosuccinate synthase 1 (ASS1) polypeptide. Also provided are related polypeptides for use in the invention. Polypeptide and mRNA therapies of the disclosure increase and/or restore deficient levels of ASS1 expression and/or activity in subjects. Polypeptides and mRNA therapies of the disclosure may be used in combination with argininosuccinate lyase polypeptides or mRNAs encoding the same.
3.20250375391LIPID NANOPARTICLE COMPOSITIONS COMPRISING SURFACE LIPID DERIVATIVES AND RELATES USES
US - 11.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19099108 Applicant ModernaTX, Inc. Inventor Yue HUI

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

4.20250375389LIPID NANOPARTICLE COMPOSITIONS COMPRISING PHOSPHOLIPID DERIVATIVES AND RELATED USES
US - 11.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19099092 Applicant ModernaTX, Inc. Inventor Jaclyn MILTON

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

5.WO/2025/250534T CELL TARGETS FOR TUBERCULOSIS VACCINES
WO - 04.12.2025
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
 Appl.No PCT/US2025/031027 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor DAVIS, Mark M.
The Mtb protein Rv2140c, specific peptide epitopes derived, and polynucleotide sequences encoding such polypeptides are disclosed herein as a useful TB antigen for generating a protective immune response to development of tuberculosis. In some embodiments the Rv2140c polypeptide or polynucleotide is formulated as a vaccine. In some embodiments the Rv2140c vaccine is administered to a naïve recipient. In some embodiments the Rv2140c vaccine is administered as a booster to a previously vaccinated to exposed individual. In some embodiments the previous vaccination is a BCG vaccination.
6.20250367128BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR LIVER TARGETED DELIVERY
US - 04.12.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 18853162 Applicant The Trustees of the University of Pennsylvania Inventor Michael Mitchell

Described are biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoids and compositions thereof. In various embodiments, the LNP selectively targets a liver cell. In other aspects, the present invention relates to methods for in vivo delivery of therapeutic nucleic acids to the liver to prevent or treat diseases or disorders using the LNP compositions of the invention.

7.WO/2025/250677COMPOSITIONS AND METHODS FOR CORRECTION OF TREX1 MUTATIONS
WO - 04.12.2025
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
 Appl.No PCT/US2025/031247 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor MINER, Jonathan
Compositions and methods for correction of RVCL-causing mutations in a TREX1 gene are provided.
8.20250367240DERIVATION OF GLUCOSE-RESPONSIVE INSULIN-SECRETING CELLS AND ORGANOIDS FROM HUMAN STOMACH CELLS AND THEIR USE TO TREAT DIABETES
US - 04.12.2025
Int.Class A61K 35/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
37Digestive system
39Pancreas; Islets of Langerhans
 Appl.No 18870864 Applicant CORNELL UNIVERSITY Inventor Qiao Joe ZHOU

The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.

9.WO/2025/244008MEASUREMENT METHOD, PROGRAM, AND HIGH-SPEED LIQUID CHROMATOGRAPH TANDEM MASS SPECTROMETER
WO - 27.11.2025
Int.Class G01N 27/62
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
62by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
 Appl.No PCT/JP2025/018148 Applicant SHIMADZU CORPORATION Inventor KUNISAWA, Akihiro
A method for measuring a creatinine correction value of a nucleoside according to the present disclosure includes a step (S10) for temporally separating a component, a step (S12) for acquiring a chromatogram of an ion derived from each component, a step (S14) for acquiring a nucleoside measurement value on the basis of a chromatogram of an ion of the nucleoside, a step (S16) for acquiring a creatinine measurement value on the basis of a chromatogram of a product ion other than the product ion having the highest ionic strength of creatinine, and a step (S18) for calculating a creatinine correction value of the nucleoside.
10.WO/2025/242766PNEUMOCOCCAL VACCINE
WO - 27.11.2025
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/EP2025/064048 Applicant ABERA BIOSCIENCE AB Inventor JONG, Wouter Simon Petrus
The present invention relates to immunogenic compositions and vaccine compositions comprising the antigens AliA or immunogenic fragments thereof and PnrA and immunogenic fragments thereof from Streptococcus pneumoniae and uses thereof in the treatment and/or prevention of infections by S. pneumoniae.
# -